A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
|
Oct 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Change of prognosis of patients with myelodysplastic syndromes during the last 30 years
|
Apr 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Good riddance to the term "refractory anemia" in myelodysplastic syndromes
|
Oct 2016
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
|
Jan 2019
|
Leuk Lymphoma.
|
myelodysplastic syndromes (MDS)
|
Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment
|
May 2015
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure
|
Mar 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes
|
May 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
YAP1 expression in myelodysplastic syndromes and acute leukemias
|
Mar 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?
|
Sep 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RELEVANCE OF PRE-TRANSPLANT DISEASE STATUS.
|
Jun 2013
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|